Gene therapy trial aims to halt rare eye disease that steals sight
NCT ID NCT06699108
First seen Jan 10, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This phase 3 study tests a gene therapy called VGR-R01 for people with Bietti Crystalline Dystrophy, a rare inherited eye disease that causes vision loss. The trial will enroll 45 adults to see if the treatment improves eyesight compared to no treatment. The goal is to control the disease and preserve vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.